Section 41-147-3 - Availability of individualized investigative treatment to eligible patients in eligible facilities

(1) A manufacturer operating within an eligible facility and pursuant to all applicable FWA laws and regulations may make available an individualized investigative treatment and an eligible patient may request an individualized investigational drug, biological product or device from an eligible facility or manufacturer operating within an eligible facility under this act. This act does not require that a manufacturer make available an individualized investigational drug, biological product, or device to an eligible patient.(2) An eligible facility or manufacturer operating within an eligible facility may do all of the following:(a) Provide an individualized investigational drug, biological product, or device to an eligible patient without receiving compensation; and(b) Require an eligible patient to pay the costs of, or the costs associated with, the manufacture of the investigational drug, biological product, or device.Added by Laws, 2024, ch. 432, SB 2858,§ 2, eff. 7/1/2024.